TG 4040 / Transgene - LARVOL DELTA

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. (PubMed, Vaccines (Basel)) - "Our findings revealed how two E2 viral proteins that differ in their capacity to form aggregates are able to enhance to different extent the HCV-specific cellular and humoral immune responses, either alone or in combination with MVA-HCV. These combined protocols of MVA-HCV/E2 could serve as a basis for the development of a more effective HCV vaccine."

Combination therapy • Journal • Hepatitis C Virus • Infectious Disease

HCVac study: Antiviral activity of TG4040 therapeutic vaccine in genotype-1 chronic HCV patients (AASLD 2011) - Presentation time: Nov 07 8:00 AM - 5:30 PM; HCVac; P2, N=153; Twenty four patients have completed 12 weeks of TG4040 monotherapy in arm C and 14 of them had a more than 0.5 log10 IU/mL viral load decrease at one or more time-points, ranging from 0.55 to more than 2 log10 IU/mL consistent with PI trial results; The results of this ongoing P2 trial confirm the antiviral activity of TG4040 therapeutic vaccine in monotherapy

Interim P2 data • Hepatitis C Virus

Transgene: Annual results 2012 and business update (Business Wire) - Final P2b data and update on TG4040 strategy will be presented by Transgene during the upcoming EASL congress of 2013 (Amsterdam, April 2013).

Anticipated P2b data • Hepatitis C Virus

Potent Anti-Hepatitis C (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-launched RNA Replicons and MVA-HCV. (PubMed, J Virol) - "Immunization of mice with the DREP vaccines as the priming immunization followed by a heterologous boost with a recombinant modified vaccinia virus Ankara (MVA) vector expressing the nearly full-length genome of HCV (MVA-HCV) induced potent and long-lasting HCV-specific CD4 and CD8 T cell immune responses that were significantly stronger than those of a homologous MVA-HCV prime/boost immunization, with the DREP-e-HCV/MVA-HCV combination the most immunogenic regimen...Here, we describe for the first time the generation of novel vaccines against HCV based on alphavirus DNA replicons expressing HCV antigens. We demonstrate that potent T cell immune responses, as well as humoral immune responses against HCV can be achieved in mice by using a combined heterologous prime/boost immunization protocol consisting in the administration of alphavirus replicon DNA vectors as a prime followed by a boost with a recombinant modified vaccinia virus Ankara vector expressing HCV antigens."

Journal • Preclinical

TG4040 in Patients With Chronic HCV (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); N=85 ➔ 0

Clinical • Enrollment change